Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.56 |
| ▸ | F2 | P00734 | 5/20 | 0.56 |
| ▸ | PLG | P00747 | 3/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16253306 | 1.00 | F10 (0.56) | F10F2PLGPRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL16236107 | 0.99 | F10 (0.56) | F10F2PLGPRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL16236104 | 0.99 | F10 (0.56) | F10F2PLGPRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL16236110 | 0.99 | F10 (0.56) | F10F2PLGPRSS1PRSS2 | |
| SCHEMBL16240173 | 0.83 | ACACB (0.57) | ACACB | |
| SCHEMBL16240171 | 0.83 | ACACB (0.57) | ACACB | |
| SCHEMBL16240170 | 0.83 | ACACB (0.57) | ACACB | |
| SCHEMBL8893118 | 0.79 | F10 (0.52) | F10F2PLGPRSS1PRSS2 | |
| SCHEMBL15634929 | 0.79 | ACACB (0.51) | F10F2ACACB | |
| SCHEMBL15634930 | 0.79 | ACACB (0.51) | F10F2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2997024-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2018-03-28 | — | — | EP | disclosed |
| EP-2997024-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2016-03-23 | — | — | EP | disclosed |
| US-9278954-B2 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-08 | — | — | US | disclosed |
| WO-2014184104-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | WO | disclosed |
| US-20140343083-A1 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343083-A1 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | ACACB, PC, ACACA | F10 4379/4885F2 2033/4885PLG 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.